Cargando…
Current and future perspectives of chimeric antigen receptors against glioblastoma
Glioblastoma multiforme (GBM) is the most malignant form of cancer in the central nervous system; even with treatment, it has a 5-year survival rate of 7.2%. The adoptive cell transfer (ACT) of T cells expressing chimeric antigen receptors (CARs) has shown a remarkable success against hematological...
Autores principales: | Zhang, Josephine, Siller-Farfán, Jesús A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9585667/ https://www.ncbi.nlm.nih.gov/pubmed/36284838 http://dx.doi.org/10.1093/immadv/ltac014 |
Ejemplares similares
-
Chimeric Antigen Receptor T Cells in Glioblastoma—Current Concepts and Promising Future
por: Kringel, Rebecca, et al.
Publicado: (2023) -
Chimeric Antigen Receptor T-Cell Therapy in Glioblastoma: Current and Future
por: Li, Long, et al.
Publicado: (2020) -
Current and Future Perspectives for Chimeric Antigen Receptor T Cells Development in Poland
por: Ślebioda, Tomasz J., et al.
Publicado: (2022) -
Inefficient exploitation of accessory receptors reduces the sensitivity of chimeric antigen receptors
por: Burton, Jake, et al.
Publicado: (2023) -
Current progress in chimeric antigen receptor T cell therapy for glioblastoma multiforme
por: Marei, Hany E., et al.
Publicado: (2021)